New tetanus antibody drug shows promise in early trial
NCT ID NCT05625477
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested an experimental drug called TNM002 in 240 healthy Chinese adults to see if it can protect against tetanus as well as the standard treatment. Participants received a single injection of TNM002 at different doses, the standard tetanus antibody, or a placebo. The main goal was to measure whether TNM002 raised tetanus-fighting antibodies to protective levels. The trial is now complete, and results will show if this new drug is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TNM002 injection (an experimental antibody)
What this could lead to
If successful, TNM002 could offer a new option to prevent tetanus after injury, potentially with fewer side effects or easier production than current treatments.
What could go wrong
This is an early-phase trial with only 240 participants, so results may not apply to everyone. The experimental drug may not work as well as existing tetanus shots, and allergic reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PKUCare Luzhong Hospital
Zibo, Shandong, China
-
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
-
Wuxi People's Hospital
Wuxi, Jiangsu, China
-
Yunnan Provincial Hospital of Traditional Chinese Medicine
Kunming, Yunnan, China